These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20043031)

  • 61. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
    Tillet Y; Maillols-Perroy AC
    Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Four Decades of Orphan Drugs and Priorities for the Future.
    Sinha MS; Stern AD; Rai AK
    N Engl J Med; 2024 Jul; 391(2):100-102. PubMed ID: 38973724
    [No Abstract]   [Full Text] [Related]  

  • 66. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
    Gorzelany JA; de Souza MP
    Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug development. Orphan drug windfalls?
    Gershon D
    Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267
    [No Abstract]   [Full Text] [Related]  

  • 71. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 72. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
    Socal MP; Parasrampuria S; Anderson GF
    Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical pharmacology and orphan drugs: an informational inventory 2006-2010.
    Bashaw ED; Fang L
    Clin Pharmacol Ther; 2012 May; 91(5):932-6. PubMed ID: 22453190
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 77. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 78. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 79. Billion-dollar market blossoms as botanicals take root.
    Glaser V
    Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256
    [No Abstract]   [Full Text] [Related]  

  • 80. Policymaking for Orphan Drugs and Its Challenges.
    Rhee TG
    AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.